drugset / Trial / NCT00032149

Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

NCT00032149

Phase 1/2 Unknown 30 enrolled Lymphoma Trials Office
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of combining filgrastim with combination chemotherapy in treating patients who have HIV-related non-Hodgkin's lymphoma.

Timeline

Start
2001-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Bleomycin Unknown Intravenous
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Etoposide Small molecule Intravenous
Subject Mitoxantrone Small molecule Intravenous
Subject Prednisolone Other / unclassified
Subject Vincristine Small molecule Intravenous
Subject filgrastim Protein / enzyme biologic Subcutaneous

Indications